ARS Pharmaceuticals has launched Neffy, a needle-free nasal spray delivering epinephrine to treat severe allergic reactions in kids aged 4 and older. Approved by the FDA, this treatment aims to ease fears associated with needle injections, potentially improving health outcomes during anaphylaxis. Families can access this innovative method, which has not seen advancements in three decades, reflecting the pressing need for child-friendly medical solutions in emergency situations. The CEO champions this tool as crucial for expanding access and confidence in administering life-saving treatment.
Richard Lowenthal, CEO of ARS Pharmaceuticals, emphasized that the needle-free option will reduce hesitation and eliminate needle-related injuries, improving access to critical treatment.
Neffy, a needle-free nasal spray epinephrine treatment, offers families a long-awaited alternative to needle-based auto-injectors, addressing a significant unmet need in anaphylaxis management.
Collection
[
|
...
]